BiotechTube

E5564

Phase 2Completed
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Sepsis

Conditions

Sepsis, Shock, Septic, Sepsis Syndrome, Septicemia, Infection

Trial Timeline

Oct 1, 2001 → Apr 1, 2005

NCT ID
NCT00046072

About E5564

E5564 is a phase 2 stage product being developed by Eisai for Sepsis. The current trial status is completed. This product is registered under clinical trial identifier NCT00046072. Target conditions include Sepsis, Shock, Septic, Sepsis Syndrome.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (2)

NCT IDPhaseStatus
NCT00756912Phase 1Terminated
NCT00046072Phase 2Completed

Competing Products

20 competing products in Sepsis

See all competitors
ProductCompanyStageHype Score
Alkaline Phosphatase + PlaceboAM-PharmaPhase 2
44
Drotrecogin alfa (activated)Eli LillyPhase 2
52
MeropenemPfizerApproved
84
ImipenemMerckApproved
85
CefiderocolShionogiPhase 1
33
eritoran tetrasodium + PlaceboEisaiPhase 3
77
Drotrecogin Alfa (Activated) + placeboEli LillyPhase 3
77
Drotrecogin alfa (activated) + PlaceboEli LillyPhase 3
77
Drotrecogin Alfa (activated)Eli LillyApproved
85
Drotrecogin alfa (activated) + PlaceboEli LillyPhase 3
77
Drotrecogin alfa (activated) + PlaceboEli LillyPhase 3
77
sPLA2 InhibitorEli LillyPhase 1/2
41
Drotrecogin alfa (activated)Eli LillyApproved
85
Drotrecogin Alfa (Activated) + Unfractionated heparin + Low molecular weight heparinEli LillyApproved
85
drotrecogin alfa (activated)Eli LillyApproved
85
drotrecogin alfa (activated)Eli LillyApproved
85
AZD9773 (CytoFab)AstraZenecaPhase 2
52
AZD9773 + PlaceboAstraZenecaPhase 2
52
AZD9773 + PlaceboAstraZenecaPhase 2
52
AZD4144 + PlaceboAstraZenecaPhase 2
52

Other Products from Eisai

MecobalaminApproved
85
MonteplaseApproved
85
E2020 + PlaceboApproved
85
Palonosetron 0.075 mg IV + Dexamethasone 10 mg IV + Promethazine 25 mg IVApproved
85
DonepezilApproved
85